Taylor H E, Ackman C F, Horowitz I
Can Med Assoc J. 1976 Dec 18;115(12):1205-8.
A multicentre, randomized clinical trial of antilymphocyte globulin (ALG) was conducted among patients who had undergone cadaver kidney transplantation; follow-up was continued for a minimum of 1 year. Of the 179 patients 92 were given conventional treatment only, while 87 were given in addition ALG (from a standardized, highly immunosuppressive, common pool of equine ALG), 20 mg/kg-d intravenously for 10 days after transplantation. The ALG-treated group had better accumulated graft survival, fewer nephrectomies, better graft function, less than half the number of acute rejection episodes and less prednisone use. There was a beneficial drug (ALG)-related effect in both the graft and the host during the first 3 months after transplantation.
在接受尸体肾移植的患者中进行了一项抗淋巴细胞球蛋白（ALG）的多中心随机临床试验；随访持续至少1年。179例患者中，92例仅接受常规治疗，而87例除常规治疗外还接受了ALG（来自标准化、高度免疫抑制的马ALG通用库），移植后静脉注射20mg/kg·d，共10天。接受ALG治疗的组累积移植物存活率更高，肾切除术更少，移植物功能更好，急性排斥反应发作次数不到一半，泼尼松用量更少。在移植后的前3个月，移植物和宿主中均存在与药物（ALG）相关的有益作用。
